In vivo silencing of a molecular target by short interfering RNA electroporation: Tumor vascularization correlates to delivery efficiency

Molecular Cancer Therapeutics

Volumn 7, Issue 1, 2008, Pages 211-221

  Takei, Yoshifumi ^a,b   Nemoto, Toshio ^c   Mu, Ping ^a   Fujishima, Tatsuya ^a   Ishimoto, Takuji ^a,b   Hayakawa, Yasuhiko ^d   Yuzawa, Yukio ^b   Matsuo, Seiichi ^b   Muramatsu, Takashi ^a   Kadomatsu, Kenji ^a  

^a Department of Biochemistry ^*  (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Kinoe Co Ltd   (Japan)

^d Nepa Gene Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ELECTROPORATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR; TUMOR VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; ELECTROPORATION; GENE SILENCING; HUMANS; MICE; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38349148685     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0319     Document Type: Article

References (47)

1. Workman P, Kaye SB. Translating basic cancer research into new cancer therapeutics. Trends Mol Med 2002;8:S1-9.
2. Smith A. Screening for drug discovery: the leading question. Nature 2002;418:453-9.
3. Lindsay MA. Target discovery. Nat Rev Drug Discov 2003;2:831-8.
4. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotideRNAs mediate interference in cultured mammalian cells. Nature 2001;411:494-8.
5. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11.
6. Carpenter AE, Sabatini DM. Systematic genome-wide screens of gene function. Nat Rev Genet 2004;5:11-22.
7. Zheng L, Liu J, Batalov S, et al. An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci U S A 2004;101:135-40.
8. Karagiannis TC, El-Osta A. Mechanism of RNA interference, in vivo and potential clinical applications. Cancer Biol Ther 2004;3:1069-74.
9. Ryther RCC, Flynt AS, Phillips JA III, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther 2005;12:5-11.
10. Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer Sci 2006;97:689-96.
11. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004;64:3365-70.
12. Ochiya T, Takahama Y, Nagahara S, et al. New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med 1999;5:707-10.
13. Honma K, Ochiya T, Nagahara S, et al. Atelocollagen-based gene transfer in cells allows high-throughput screening of gene functions. Biochem Biophys Res Commun 2001;289:1075-81.
14. Minakuchi Y, Takeshita F, Kosaka N, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004;32:e109.
15. Maruyama H, Ataka K, Higuchi N, Sakamoto F, Gejyo F, Miyazaki J. Skin-targeted gene transfer using in vivo electroporation. Gene Ther 2001;8:1808-12.
16. Coster HG. A quantitative analysis of the voltage-current relationships of fixed charge membranes and the associated property of "punch- through". Biophys J 1965;5:669 -86.
17. Wong TK, Neumann E. Electric field mediated gene transfer. Biochem Biophys Res Commun 1982;107:584-7.
18. Kong XC, Barzaghi P, Ruegg MA. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep 2004;5:183-8.
19. Matsuda T, Cepko CL. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci U S A 2004;101:16-22.
20. Takahashi Y, Nishikawa M, Kobayashi N, Takakura Y. Gene silencing in primary and metastatic tumors by small interfering RNA delivery in mice: quantitative analysis using melanoma cells expressing firefly and sea pansy luciferases. JControl Release 2005;105:332-43.
21. Golzio M, Mazzolini L, Moller P, Rols MP, Teissie J. Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery. Gene Ther 2005;12:246-51.
22. Takei Y, Kadomatsu K, Goto T, Muramatsu T. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer 2006;107:864-73.
23. Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 1996;7:213-21.
24. Koshida Y, Kuranami M, Watanabe M. Interaction between stromal fibroblasts and colorectal cancer cells in the expression of vascular endothelial growth factor. J Surg Res 2006;134:270-7.
25. Takei Y, Kadomatsu K, Matsuo S, et al. Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 2001;61:8486-91.
26. Takei Y, Kadomatsu K, Itoh H, et al. 5′-,3′-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy. JBiol Chem 2002;277:23800-6.
27. Takei Y, Kadomatsu K, Yuasa K, Sato W, Muramatsu T. Morpholino antisense oligomer targeting human midkine: its application for cancer therapy. Int JCancer 2005;114:490-7.
28. Pliquett U, Prausnitz MR. Electrical impedance spectroscopy for rapid and noninvasive analysis of skin electroporation. In: Jaroszeski MJ, Heller R, Gilbert R, editors. Methods in molecular medicine electrochemotherapy, electrogenetherapy, and transdermal drug delivery. Electrically mediated delivery of molecules to cells. Totowa (NJ): Human Press, Inc.; 2000. p. 377-406.
29. Tur-Kaspa R, Teicher L, Levine BJ, Skoultchi AI, Shafritz DA. Use of electroporation to introduce biologically active foreign genes into primary rat hepatocytes. Mol Cell Biol 1986;6:716-8.
30. Taketo A. DNA transfection of Escherichia coli by electroporation. Biochim Biophys Acta 1988;949:318-24.
31. Jaroszeski MJ, Gilbert R, Nicolau C, Heller R. In vivo gene delivery by electroporation. Adv Drug Deliv Rev 1999;35:131-7.
32. Heller R, Jaroszeski M, Atkin A, et al. In vivo gene electroinjection and expression in rat liver. FEBS Lett 1996;389:225-8.
33. Nishi T, Yoshizato K, Yamashiro S, et al. High-efficiency in vivo gene transfer using intraarterial plasmid DNA injection following in vivo electroporation. Cancer Res 1996;56:1050-5.
34. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998;16:867-70.
35. Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R. Electroporation- enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 2006;6:243-73.
36. Harada N, Shimada M, Okano S, et al. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. JImmunol 2004;173:6635-44.
37. Yamashita YI, Shimada M, Hasegawa H, et al. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 2001;61:1005-12.
38. Hofmann GA. Instrumentation and electrodes for in vivo electroporation. In: Jaroszeski MJ, Heller R, Gilbert R, editors. Methods in molecular medicine electrochemotherapy, electrogenetherapy, and transdermal drug delivery. Electrically mediated delivery of molecules to cells. Totowa (NJ): Human Press, Inc.; 2000. p. 37-61.
39. Heller R, Jaroszeski MJ, Glass LF, et al. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer 1996;77:964-71.
40. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
41. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
42. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998;49:407-24.
43. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
44. Kim J, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-4.
45. Brekken RF, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF-A) receptor 2 (KDR/Flk-1) activity by a monoclonal antibody blocks tumor growth in mice. Cancer Res 2000;60:5117-24.
46. Holash J, Davis S, Papadopoulos N, et al. VEGF-A-Trap: a VEGF-A blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-8.
47. Chen HX, Gore-Langton RE, Cheson BD. Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology 2001;15:1017.